Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities

Rahul Deb, Marcelo D. T. Torres, Miroslav Boudný, Markéta Koběrská, Floriana Cappiello, Miroslav Popper, Kateřina Bendová, Martina Drabinová, Adelheid Hanáčková, Katy Jeannot, Miloš Petřík, Maria Luisa Mangoni, Gabriela Balíková Novotná, Marek Mráz, César de la Fuente‐Núñez, Robert VáchaJournal of Medicinal Chemistry 2024 · DOI

TL;DR

This paper presents a computational approach to design novel antimicrobial and anticancer peptides that form pores in cell membranes. By systematically mutating a known pore-forming peptide and using molecular simulations, they identified key sequence modifications that enhance both efficacy and selectivity, leading to potent therapeutic candidates with low toxicity.

What Problem Does This Paper Address?

The rise of antibiotic resistance and the challenges in treating cancer necessitate the development of new therapeutic agents. Pore-forming peptides (PFPs) offer a promising avenue due to their ability to disrupt bacterial and cancer cell membranes. However, optimizing these peptides for clinical use is hindered by a poor understanding of how their sequence dictates their function. This paper aims to bridge this gap by computationally designing and experimentally validating PFPs with improved antimicrobial and anticancer activities, focusing on enhancing membrane affinity and pore stability.

Methods

The researchers employed a multi-pronged approach:

  • Computational Design: They used molecular dynamics (MD) simulations with the coarse-grained Martini force field to predict the stability of transmembrane barrel-stave pores (TBPs) formed by mutated peptides. They explored various mutation types, including changes in aromatic stacking, salt bridges, net charge, termini, amphipathicity, and specific residue substitutions (Arg, His).
  • Liposome Leakage Assays: These experiments were used to quantify the pore-forming ability of the designed peptides by measuring the release of a fluorescent dye (calcein) from artificial lipid vesicles mimicking bacterial membranes.
  • Atomic Force Microscopy (AFM): AFM was used to directly visualize the pores formed by peptides on supported lipid bilayers, providing a direct look at the peptide-membrane interaction and pore morphology.
  • In Vitro Antimicrobial and Cytotoxicity Assays: The designed peptides were tested against a panel of Gram-positive and Gram-negative bacteria (including ESKAPEE pathogens) to determine their minimum inhibitory concentrations (MICs). Their toxicity to human cell lines and reconstructed human skin models was also assessed.
  • In Vivo Studies: Promising candidates were evaluated in a murine deep thigh infection model and a wound infection model to assess their anti-infective efficacy and potential for wound healing.
  • pH-Dependent Activity Studies: The researchers investigated the effect of pH on both antimicrobial and anticancer activity, particularly for histidine-containing variants.

Datasets

The study utilized a previously designed peptide (KDFA2i+9-NH2, referred to as LP1) as a starting point. They generated 46 mutant peptides based on this scaffold. The experimental validation involved testing these peptides against various bacterial strains (including ESKAPEE pathogens) and a panel of 22 human cell lines (cancerous and non-cancerous).

Key Insights and Ideas

  • Pore stability is necessary but not sufficient: While stable pore formation is crucial, it's not the sole determinant of antimicrobial efficacy. Optimizing peptide affinity for bacterial and cancer cell membranes is equally critical, especially for achieving submicromolar activity.
  • Net charge optimization is key: Increasing the net positive charge of peptides can enhance antimicrobial activity by improving affinity for negatively charged bacterial membranes, but there's an optimal threshold beyond which activity may decrease.
  • pH-sensitivity offers therapeutic potential: The histidine-containing variant (LP40) demonstrated pH-dependent antimicrobial and anticancer activity, suggesting a strategy for selective targeting of acidic environments found in tumors and infections.
  • Computational design accelerates discovery: The study highlights the power of combining molecular simulations with experimental validation to rapidly identify and optimize potent therapeutic peptides.

Key Results

  • Improved Antimicrobial Activity: Several designed peptides exhibited significantly higher antimicrobial activity than the parent peptide, with some achieving submicromolar MICs against antibiotic-resistant ESKAPEE pathogens. For instance, LP18 showed a four-fold increase in activity against A. baumannii.
  • Low Cytotoxicity: The most potent antimicrobial peptides demonstrated low toxicity to human cells and skin models, with therapeutic indices (ratio of IC50 to MIC) often exceeding 35.
  • Systemic Anti-infective Activity: In a murine deep thigh infection model, LP1 showed significant reduction in bacterial load comparable to conventional antibiotics.
  • pH-Dependent Anticancer Activity: The histidine-variant LP40 showed enhanced anticancer activity at lower pH, consistent with the acidic microenvironment of tumors.
  • AFM Visualization: Atomic force microscopy confirmed the formation of membrane pores by the designed peptides, visualizing their direct interaction with lipid bilayers.

Limitations and Future Work

  • Correlation Complexity: The study found a complex relationship between simulated TBP stability and experimental pore-forming activity, as well as between pore formation and antimicrobial activity. This suggests that other factors beyond pore stability are critical.
  • Proteolytic Degradation: Peptides can be susceptible to degradation by host proteases, which can limit their efficacy and duration of action. This susceptibility increases with higher net charge.
  • Gram-Positive Bacteria Resistance: The peptides showed less effectiveness against Gram-positive bacteria, potentially due to differences in cell wall composition.
  • Future Directions: The authors suggest further optimization of peptide affinity, exploration of different administration routes, and investigation into the role of other factors like membrane insertion barriers and susceptibility to degradation. They also propose further studies on the interplay between sequence, affinity, and function in living systems.

Summary updated

Abstract

Peptides that form transmembrane barrel-stave pores are potential alternative therapeutics for bacterial infections and cancer. However, their optimization for clinical translation is hampered by a lack of sequence-function understanding. Recently, we have <i>de novo</i> designed the first synthetic barrel-stave pore-forming antimicrobial peptide with an identified function of all residues. Here, we systematically mutate the peptide to improve pore-forming ability in anticipation of enhanced activity. Using computer simulations, supported by liposome leakage and atomic force microscopy experiments, we find that pore-forming ability, while critical, is not the limiting factor for improving activity in the submicromolar range. Affinity for bacterial and cancer cell membranes needs to be optimized simultaneously. Optimized peptides more effectively killed antibiotic-resistant ESKAPEE bacteria at submicromolar concentrations, showing low cytotoxicity to human cells and skin model. Peptides showed systemic anti-infective activity in a preclinical mouse model of <i>Acinetobacter baumannii</i> infection. We also demonstrate peptide optimization for pH-dependent antimicrobial and anticancer activity.
BibTeX
@article{deb2024computational,
  author = {Rahul Deb and Marcelo D. T. Torres and Miroslav Boudný and Markéta Koběrská and Floriana Cappiello and Miroslav Popper and Kateřina Bendová and Martina Drabinová and Adelheid Hanáčková and Katy Jeannot and Miloš Petřík and Maria Luisa Mangoni and Gabriela Balíková Novotná and Marek Mráz and César de la Fuente‐Núñez and Robert Vácha},
  title = {{Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities}},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00912},
}
Figure